These results potentially offer a new approach to improving the effectiveness of anticancer therapy using combinations of an ATR inhibitor with genotoxic drugs and/or immunomodulators, with promising early signals of efficacy in lung cancer, melanoma, and gastric cancer. This evidence concerns the gene ATR and lung cancer.